Elegen, a pioneering company at the forefront of the synthetic biology revolution, has successfully secured $35,000,000 in funding. The company, based in San Carlos, CA, is dedicated to developing cutting-edge technologies that allow for rapid and cost-effective DNA writing, with a focus on enhancing the reprogramming of biology to address significant global challenges. Led by Dr. Matthew Hill and backed by prominent investors such as Andreessen Horowitz, 8VC, and KdT, Elegen is poised to drive innovation in biotechnology solutions. With a team of esteemed scientists and entrepreneurs, including Dr. Marc Unger, Elegen is well-positioned to propel its groundbreaking technologies from invention to commercial success. This substantial funding injection will further support Elegen's mission to revolutionize biologic solutions and harness the potential of synthetic biology to improve human lives on a grand scale.












